Eton Pharmaceuticals (NASDAQ:ETON) Shares Down 4.4% - Here's Why

Key Points

• Eton Pharmaceuticals shares fell 4.4% to about $59.93 in Friday trading, with volume down 86% from the average session.
• Analyst sentiment remains generally positive: the stock has a consensus “Moderate Buy” rating and a $67.50 price target, supported by recent target increases to as high as $70.
• Eton exceeded quarterly expectations, reporting $0.43 in EPS versus $0.19 expected and revenue of $37.59 million versus $27.11 million expected; however, insiders have recently sold shares, including 25,000 shares sold by insider David Krempa.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report)'s stock price traded down 4.4% during trading on Friday . The stock traded as low as $59.26 and last traded at $59.93. Approximately 57,994 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 423,626 shares. The stock had previously closed at $62.67.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ETON shares. Zacks Research upgraded shares of Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday. Weiss Ratings reissued a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, July 28th. B. Riley Financial restated a "buy" rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Finally, Canaccord Genuity Group increased their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a "buy" rating in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $67.50.

Eton Pharmaceuticals Stock Performance

The stock has a market cap of $1.69 billion, a P/E ratio of 155.37 and a beta of 0.86. The company's 50 day moving average price is $44.62 and its 200-day moving average price is $31.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The firm had revenue of $37.59 million for the quarter, compared to analysts' expectations of $27.11 million. Equities analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Insider Transactions at Eton Pharmaceuticals

In other news, insider David Krempa sold 25,000 shares of the business's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the completion of the transaction, the insider directly owned 37,025 shares in the company, valued at $2,409,216.75. The trade was a 40.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of the firm's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the sale, the director owned 50,000 shares in the company, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 16.49% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Quarry LP purchased a new position in Eton Pharmaceuticals in the third quarter worth about $37,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $41,000. Toth Financial Advisory Corp bought a new stake in shares of Eton Pharmaceuticals in the second quarter worth approximately $43,000. Caitong International Asset Management Co. Ltd bought a new position in Eton Pharmaceuticals during the fourth quarter valued at approximately $44,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Eton Pharmaceuticals in the second quarter worth approximately $90,000. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source